Total
0
Shares
Respiri (ASX:RSH) - Ambassador, Michael Clarke - The Market Herald
Ambassador, Michael Clarke
Source: Respiri
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Respiri (RSH) has received United States Food and Drug Administration (FDA) clearance for its wheezing aid, Wheezo
  • Wheezo monitors wheezing to manage and improve asthma
  • With the green tick from the FDA, the company can now market and sell the technology in the United States
  • On the market this afternoon, Respiri is in the grey and trading at 17 cents per share

Respiri (RSH) has received United States Food and Drug Administration (FDA) clearance for Wheezo.

Wheezo monitors wheezing to help manage and improve asthma. The technology can also share data with caregivers, physicians and other health care professionals.

With the green tick from the FDA, the company can now market and sell its technology in the United States.

Asthma is a significant problem in the U.S., with around 8 per cent of the population and 7.5 per cent of children living with the disease.

Respiri is aiming to launch Wheezo in the U.S. market in the third quarter of 2022.

CEO Marjan Mikel says FDA approval is a major milestone as Respiri continues to expand its footprint for Wheezo.

"The FDA is one of the most stringent regulatory bodies in the world and this clearance further validates the efficacy and utility of our wheezo device and algorithm. To our knowledge the first time the FDA has cleared a device/mobile application for the detection, recording and changes of wheeze rates," he said.

"This represents a step-change in technology for patients with respiratory wheeze seeking an effective, replicable and rapid device measurement and associated App that monitors this important measurement of lung function," he added.

Notably, the product has been granted over-the-counter approval, which means Wheezo can be provided to patients with or without a prescription.

"Further, although we remain heavily focused on asthma, we are pleased that the approval was indication agnostic where wheezo can be used in any respiratory condition where wheeze is a symptom," Marjan said.

On the market this afternoon, Respiri is in the grey and trading at 17 cents per share at 1:31 pm AEDT.

RSH by the numbers
More From The Market Herald
Imricor Medical Systems (ASX:IMR) - Chair and CEO, Steve Wedan - The Market Herald

" Imricor Medical Systems (ASX:IMR) signs agreement with MiRTLE Medical

Imricor Medical Systems (IMR) has signed an agreement with MiRTLE Medical for its 12-lead ECG system.
Telix Pharmaceuticals (ASX:TLX) - CFO, Doug Cubbin - The Market Herald

" Telix Pharmaceuticals (ASX:TLX) bags $12.1m R&D tax refund, increases overseas finding to $139m

Telix Pharmaceuticals (TLX) has pocketed a research and development (R&D) tax refund of $12.1 million for eligible activities undertaken in the 2020 calenda…
Mach7 Technologies (ASX:M7T) - CEO, Mike Lampron - The Market Herald

" Mach7 (ASX:M7T) provides PACS Solution to Trinity Health in US

Mach7 Technologies (M7T) has received purchase orders for its software and services from Trinity Health totalling $3.6 million.
Pfizer tests new antiviral pill

" Pfizer tests new antiviral pill

Major vaccine producer Pfizer says it will start trials for an antiviral pill for those who have been exposed to COVID-19.